Sareum to Present at Oncology Leadership Meeting

RNS Number : 4224G

Sareum Holdings PLC

12 May 2011

 

(AIM: SAR)

12 May 2011

SAREUM HOLDINGS PLC
("Sareum" or the "Company") 

Sareum to Present at Oncology Leadership Meeting

Sareum (AIM: SAR), the specialist cancer drug discovery business, is pleased to announce that Dr John Reader, Chief Scientific Officer, ("CSO"), will present Sareum's Aurora+FLT3 Kinase cancer research programme at the inaugural Life Science Leadership Series conference, held in Cambridge, UK, today.

This series of events is organised by One Nucleus, the membership organisation for international life science and healthcare companies, with oncology being the focus of this first event of the series.

Sareum's CSO, Dr John Reader, commented: "This exciting meeting offers us an ideal opportunity to present one of our leading cancer research programmes to representatives from international pharmaceutical and biotechnology companies."

Sareum Holdings plc
Tim Mitchell	01223 497 700
Merchant Securities Limited (Nomad)
Simon Clements	020 7628 2200
Hybridan LLP (Broker)
Claire Noyce	020 7947 4350

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery company, headquartered in Cambridge UK, that is focused on producing targeted small molecule therapeutics to address unmet medical needs, primarily in cancer. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum's Chk1 kinase cancer research programme is a joint research collaboration with The Institute of Cancer Research and Cancer Research Technology Limited. Novel chemical compounds developed by the collaboration have been shown to increase the effectiveness of current cancer therapeutics in in-vivo cancer models.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora, VEGFR-3, ALK, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.

Sareum Holdings plc joined the AIM market of the London Stock Exchange in October 2004, trading under the symbol SAR.  For further information, please visit www.sareum.co.uk

 

END

 

 

NRAMMGMKKMDGMZM